Restricted accessResearch articleFirst published online 2019-08
Alpha-1-Antitrypsin Promoter Improves the Efficacy of an Adeno-Associated Virus Vector for the Treatment of Mitochondrial Neurogastrointestinal Encephalomyopathy
Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE) is a devastating disease caused by mutations in TYMP, which encodes thymidine phosphorylase (TP). In MNGIE patients, TP dysfunction results in systemic thymidine and deoxyuridine overload, which interferes with mitochondrial DNA replication. Preclinical studies have shown that gene therapy using a lentiviral vector targeted to hematopoietic stem cells or an adeno-associated virus (AAV) vector transcriptionally targeted to liver are feasible approaches to treat MNGIE. Here, we studied the effect of various promoters (thyroxine-binding globulin [TBG], phosphoglycerate kinase [PGK], hybrid liver-specific promoter [HLP], and alpha-1-antitrypsin [AAT]) and DNA configuration (single stranded or self complementary) on expression of the TYMP transgene in the AAV8 serotype in a murine model of MNGIE. All vectors restored liver TP activity and normalized nucleoside homeostasis in mice. However, the liver-specific promoters TBG, HLP, and AAT were more effective than the constitutive PGK promoter, and the self-complementary DNA configuration did not provide any therapeutic advantage over the single-stranded configuration. Among all constructs, only AAV-AAT was effective in all mice treated at the lowest dose (5 × 1010 vector genomes/kg). As use of the AAT promoter will likely minimize the dose needed to achieve clinical efficacy as compared to the other promoters tested, we propose using the AAT promoter in the vector eventually designed for clinical use.
Get full access to this article
View all access options for this article.
References
1.
NishinoI, SpinazzolaA, HiranoM. Thymidine phosphorylase gene mutations in MNGIE, a human mitochondrial disorder. Science, 1999; 283:689–692.
2.
GaroneC, TadesseS, HiranoM. Clinical and genetic spectrum of mitochondrial neurogastrointestinal encephalomyopathy. Brain, 2011; 134:3326–3332.
3.
MartiR, NishigakiY, HiranoM. Elevated plasma deoxyuridine in patients with thymidine phosphorylase deficiency. Biochem Biophys Res Commun, 2003; 303:14–18.
4.
LopezLC, AkmanHO, Garcia-CazorlaA, et al.Unbalanced deoxynucleotide pools cause mitochondrial DNA instability in thymidine phosphorylase-deficient mice. Hum Mol Genet, 2009; 18:714–722.
5.
PontarinG, FerraroP, ValentinoML, et al.Mitochondrial DNA depletion and thymidine phosphate pool dynamics in a cellular model of mitochondrial neurogastrointestinal encephalomyopathy. J Biol Chem, 2006; 281:22720–22728.
6.
Gonzalez-VioqueE, Torres-TorronterasJ, AndreuAL, et al.Limited dCTP availability accounts for mitochondrial DNA depletion in mitochondrial neurogastrointestinal encephalomyopathy (MNGIE). PLoS Genet, 2011; 7:e1002035.
7.
GiordanoC, SebastianiM, PlazziG, et al.Mitochondrial neurogastrointestinal encephalomyopathy: Evidence of mitochondrial DNA depletion in the small intestine. Gastroenterology, 2006; 130:893–901.
8.
NishigakiY, MartiR, CopelandWC, et al.Site-specific somatic mitochondrial DNA point mutations in patients with thymidine phosphorylase deficiency. J Clin Invest, 2003; 111:1913–1921.
9.
NishigakiY, MartiR, HiranoM. ND5 is a hot-spot for multiple atypical mitochondrial DNA deletions in mitochondrial neurogastrointestinal encephalomyopathy. Hum Mol Genet, 2004; 13:91–101.
10.
LaraMC, WeissB, IllaI, et al.Infusion of platelets transiently reduces nucleoside overload in MNGIE. Neurology, 2006; 67:1461–1463.
11.
MoranNF, BainMD, MuqitMM, et al.Carrier erythrocyte entrapped thymidine phosphorylase therapy for MNGIE. Neurology, 2008; 71:686–688.
12.
SpinazzolaA, MartiR, NishinoI, et al.Altered thymidine metabolism due to defects of thymidine phosphorylase. J Biol Chem, 2002; 277:4128–4133.
13.
YavuzH, OzelA, ChristensenM, et al.Treatment of mitochondrial neurogastrointestinal encephalomyopathy with dialysis. Arch Neurol, 2007; 64:435–438.
14.
HalterJP, MichaelW, SchupbachM, et al.Allogeneic haematopoietic stem cell transplantation for mitochondrial neurogastrointestinal encephalomyopathy. Brain, 2015; 138:2847–2858.
15.
HiranoM, MartiR, CasaliC, et al.Allogeneic stem cell transplantation corrects biochemical derangements in MNGIE. Neurology, 2006; 67:1458–1460.
16.
SicurelliF, CarluccioMA, ToraldoF, et al.Clinical and biochemical improvement following HSCT in a patient with MNGIE: 1-year follow-up. J Neurol, 2012; 259:1985–1987.
17.
D'AngeloR, RinaldiR, PironiL, et al.Liver transplant reverses biochemical imbalance in mitochondrial neurogastrointestinal encephalomyopathy. Mitochondrion, 2017; 34:101–102.
18.
De GiorgioR, PironiL, RinaldiR, et al.Liver transplantation for mitochondrial neurogastrointestinal encephalomyopathy. Ann Neurol, 2016; 80:448–455.
19.
HalterJ, SchupbachWM, CasaliC, et al.Allogeneic hematopoietic SCT as treatment option for patients with mitochondrial neurogastrointestinal encephalomyopathy (MNGIE): A consensus conference proposal for a standardized approach. Bone Marrow Transplant, 2011; 46:330–337.
20.
Torres-TorronterasJ, GomezA, EixarchH, et al.Hematopoietic gene therapy restores thymidine phosphorylase activity in a cell culture and a murine model of MNGIE. Gene Ther, 2011; 18:795–806.
21.
Torres-TorronterasJ, Cabrera-PerezR, BarbaI, et al.Long-term restoration of thymidine phosphorylase function and nucleoside homeostasis using hematopoietic gene therapy in a murine model of mitochondrial neurogastrointestinal encephalomyopathy. Hum Gene Ther, 2016; 27:656–667.
22.
Hacein-Bey-AbinaS, Von KalleC, SchmidtM, et al.LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science, 2003; 302:415–419.
23.
Torres-TorronterasJ, ViscomiC, Cabrera-PerezR, et al.Gene therapy using a liver-targeted AAV vector restores nucleoside and nucleotide homeostasis in a murine model of MNGIE. Mol Ther, 2014; 22:901–907.
24.
Torres-TorronterasJ, Cabrera-PerezR, Vila-JuliaF, et al.Long-term sustained effect of liver-targeted adeno-associated virus gene therapy for mitochondrial neurogastrointestinal encephalomyopathy. Hum Gene Ther, 2018; 29:708–718.
25.
CalcedoR, WilsonJM. Humoral Immune Response to AAV. Frontiers in immunology, 2013; 4:341.
26.
MingozziF, HighKA. Immune responses to AAV vectors: Overcoming barriers to successful gene therapy. Blood, 2013; 122:23–36.
27.
RogersGL, MartinoAT, AslanidiGV, et al.Innate immune responses to AAV vectors. Front Microbiol, 2011; 2:194.
28.
PiedraJ, OntiverosM, MiravetS, et al.Development of a rapid, robust, and universal picogreen-based method to titer adeno-associated vectors. Hum Gene Ther Methods, 2015; 26:35–42.
29.
BradfordMM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem, 1976; 72:248–254.
30.
ValentinoML, MartiR, TadesseS, et al.Thymidine and deoxyuridine accumulate in tissues of patients with mitochondrial neurogastrointestinal encephalomyopathy (MNGIE). FEBS Lett, 2007; 581:3410–3414.
31.
McIntoshJ, LentingPJ, RosalesC, et al.Therapeutic levels of FVIII following a single peripheral vein administration of rAAV vector encoding a novel human factor VIII variant. Blood, 2013; 121:3335–3344.
32.
MiaoCH, OhashiK, PatijnGA, et al.Inclusion of the hepatic locus control region, an intron, and untranslated region increases and stabilizes hepatic factor IX gene expression in vivo but not in vitro. Mol Ther, 2000; 1:522–532.
33.
YadakR, Cabrera-PerezR, Torres-TorronterasJ, et al.Preclinical efficacy and safety evaluation of hematopoietic stem cell gene therapy in a mouse model of MNGIE. Mol Ther Methods Clin Dev, 2018; 8:152–165.
34.
GeorgeLA, SullivanSK, GiermaszA, et al.Hemophilia B gene therapy with a high-specific-activity factor IX variant. N Engl J Med, 2017; 377:2215–2227.
35.
NathwaniAC, ReissUM, TuddenhamEG, et al.Long-term safety and efficacy of factor IX gene therapy in hemophilia B. N Engl J Med, 2014; 371:1994–2004.
36.
NathwaniAC, RosalesC, McIntoshJ, et al.Long-term safety and efficacy following systemic administration of a self-complementary AAV vector encoding human FIX pseudotyped with serotype 5 and 8 capsid proteins. Mol Ther, 2011; 19:876–885.
37.
MartinoAT, SuzukiM, MarkusicDM, et al.The genome of self-complementary adeno-associated viral vectors increases Toll-like receptor 9-dependent innate immune responses in the liver. Blood, 2011; 117:6459–6468.
38.
MannoCS, PierceGF, ArrudaVR, et al.Successful transduction of liver in hemophilia by AAV-factor IX and limitations imposed by the host immune response. Nat Med, 2006; 12:342–347.
39.
MingozziF, MausMV, HuiDJ, et al.CD8(+) T-cell responses to adeno-associated virus capsid in humans. Nat Med, 2007; 13:419–422.
40.
ChandlerRJ, LaFaveMC, VarshneyGK, et al.Vector design influences hepatic genotoxicity after adeno-associated virus gene therapy. J Clin Invest, 2015; 125:870–880.
41.
LisowskiL, DaneAP, ChuK, et al.Selection and evaluation of clinically relevant AAV variants in a xenograft liver model. Nature, 2014; 506:382–386.
42.
VercauterenK, HoffmanBE, ZolotukhinI, et al.Superior in vivo transduction of human hepatocytes using engineered AAV3 capsid. Mol Ther, 2016; 24:1042–1049.
43.
WuZ, SunJ, ZhangT, et al.Optimization of self-complementary AAV vectors for liver-directed expression results in sustained correction of hemophilia B at low vector dose. Mol Ther, 2008; 16:280–289.
BellP, WangL, ChenSJ, et al.Effects of self-complementarity, codon optimization, transgene, and dose on liver transduction with AAV8. Hum Gene Ther Methods, 2016; 27:228–237.
46.
WuT, TopferK, LinSW, et al.Self-complementary AAVs induce more potent transgene product-specific immune responses compared to a single-stranded genome. Mol Ther, 2012; 20:572–579.
47.
Lopez-EstevezS, FerrerG, Torres-TorronterasJ, et al.Thymidine phosphorylase is both a therapeutic and a suicide gene in a murine model of mitochondrial neurogastrointestinal encephalomyopathy. Gene Ther, 2014; 21:673–681.
48.
ChenSJ, SanmiguelJ, LockM, et al.Biodistribution of AAV8 vectors expressing human low-density lipoprotein receptor in a mouse model of homozygous familial hypercholesterolemia. Hum Gene Ther Clin Dev, 2013; 24:154–160.
49.
CarlsonJA, RogersBB, SifersRN, et al.Multiple tissues express alpha 1-antitrypsin in transgenic mice and man. J Clin Invest, 1988; 82:26–36.
50.
KelseyGD, PoveyS, BygraveAE, et al.Species- and tissue-specific expression of human alpha 1-antitrypsin in transgenic mice. Genes Dev, 1987; 1:161–171.
51.
SifersRN, CarlsonJA, CliftSM, et al.Tissue specific expression of the human alpha-1-antitrypsin gene in transgenic mice. Nucleic Acids Res, 1987; 15:1459–1475.
52.
SimpsonRJ, KalraH, MathivananS. ExoCarta as a resource for exosomal research. J Extracell Vesicles, 2012; 1.
53.
FerraroP, PontarinG, CroccoL, et al.Mitochondrial deoxynucleotide pools in quiescent fibroblasts: a possible model for mitochondrial neurogastrointestinal encephalomyopathy (MNGIE). J Biol Chem, 2005; 280:24472–24480.
54.
MartiR, SpinazzolaA, TadesseS, et al.Definitive diagnosis of mitochondrial neurogastrointestinal encephalomyopathy by biochemical assays. Clin Chem, 2004; 50:120–124.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
